Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003790 · ClinicalTrials.gov registry record
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
A clinical trial, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 496
- Enrollment target
NCT00003790 is a clinical trial that has completed, run by Children's Oncology Group. The registered enrollment target is 496 participants.
The verdict
NCT00003790 has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 496 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures may improve the ability to detect residual disease. PURPOSE: Clinical trial to detect the presence of residual disease in children who are receiving therapy for acute myeloid leukemia or myelodysplastic syndrome.
Interventions
- GENETIC polymerase chain reaction
- OTHER flow cytometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 1995-02 |
| Est. Completion | 2006-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003790
The ClinicalTrials.gov registry entry for NCT00003790 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which polymerase chain reaction is the first listed.
NCT00003790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003790 about?
NCT00003790 is a clinical study titled "Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome". RATIONALE: Diagnostic procedures may improve the ability to detect residual disease. PURPOSE: Clinical trial to detect the presence of residual disease in children who are receiving therapy for acute myeloid leukemia or myelodysplastic syndrome.
What is the current status of trial NCT00003790?
This trial is currently completed. The enrollment target is 496 participants. The study started on 1995-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00003790?
The interventions under investigation include: polymerase chain reaction (GENETIC), flow cytometry (OTHER).
Who is sponsoring clinical trial NCT00003790?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.